GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unjha Formulations Ltd (BOM:531762) » Definitions » Debt-to-EBITDA

Unjha Formulations (BOM:531762) Debt-to-EBITDA : 0.00 (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Unjha Formulations Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Unjha Formulations's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.0 Mil. Unjha Formulations's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.0 Mil. Unjha Formulations's annualized EBITDA for the quarter that ended in Dec. 2024 was ₹10.0 Mil. Unjha Formulations's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Unjha Formulations's Debt-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest Debt-to-EBITDA Ratio of Unjha Formulations was 1.48. The lowest was 0.00. And the median was 0.79.

BOM:531762's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

Unjha Formulations Debt-to-EBITDA Historical Data

The historical data trend for Unjha Formulations's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unjha Formulations Debt-to-EBITDA Chart

Unjha Formulations Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Unjha Formulations Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Unjha Formulations's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unjha Formulations's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Unjha Formulations's Debt-to-EBITDA falls into.


;
;

Unjha Formulations Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Unjha Formulations's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Unjha Formulations's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Unjha Formulations  (BOM:531762) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Unjha Formulations Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Unjha Formulations's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Unjha Formulations Business Description

Traded in Other Exchanges
N/A
Address
Khali Char Rasta, State Highway, Sidhpur, Khali, Patan, GJ, IND, 384151
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.

Unjha Formulations Headlines

No Headlines